Daiichi Sankyo
Madan Kundu is a seasoned biostatistician with extensive experience in the pharmaceutical industry, currently serving as Director of Biostatistics at Daiichi Sankyo, Inc. since October 2020, where responsibilities include project statistics for early-phase oncology assets and supervising related internships. Prior roles include Manager of Statistics at AbbVie, leading statistical efforts for phase 3 and phase 4 clinical trials, and Principal Biostatistician at Novartis Oncology, focusing on trials related to neuro-endocrinal tumors and CAR-T therapy. Madan's academic background includes a PhD in Biostatistics from Indiana University School of Medicine, complemented by master's and bachelor's degrees in Agricultural Statistics and Agriculture, respectively. Additional positions reflect a strong foundation in statistical analysis and consultation across various clinical research projects.
This person is not in any teams
This person is not in any offices
Daiichi Sankyo
21 followers
Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Daiichi Sankyo Group and Ranbaxy Group. The Daiichi Sankyo Group segment comprises of Daiichi Sankyo Co., Ltd. and its subsidiaries. The Ranbaxy Group segment includes its core company, Ranbaxy Laboratories Ltd. Both group segments deal with business activities in prescription drugs and general pharmaceutical products. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.